Evidence Grade C — Moderate human evidence. 65 published studies, 35 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
KPV is a synthetic tripeptide made from the three end amino acids of alpha-MSH, a natural hormone involved in inflammation control. It has no approval from any regulatory agency and no human clinical trials have been conducted. The evidence consists entirely of cell culture studies and mouse models of intestinal inflammation.
KPV is also known by these brand and alternate names:
65 published studies: 35 human, 18 animal, 10 in-vitro, 8 reviews
KPV has no marketing authorisation from any regulatory agency. No human clinical trials have been conducted. The preclinical evidence consists of cell culture studies and mouse models of colitis.
The absence of human safety data, pharmacokinetic data, dosing studies, and efficacy trials means that KPV's effects in humans are entirely uncharacterised. Products available through unregulated channels lack pharmaceutical quality assurance.
Research in cell culture and animal models suggests KPV may reduce inflammatory signalling, potentially through inhibition of the NF-kappaB pathway. Unlike its parent molecule alpha-MSH, KPV does not appear to activate melanocortin receptors, meaning it does not affect pigmentation or appetite pathways. These observations are from preclinical studies only and have not been confirmed in humans.
Research in animal models and cell cultures suggests KPV may reduce inflammatory signalling, potentially through pathways different from its parent molecule alpha-MSH. Unlike alpha-MSH, it does not appear to affect pigmentation or appetite. No human safety data, pharmacokinetic data, dosing studies, or efficacy trials exist. The compound's effects in humans are entirely unknown. As a tripeptide, it is likely rapidly degraded by enzymes in the body, raising questions about bioavailability after injection. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for KPV sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
KPV is a synthetic tripeptide (Lys-Pro-Val), MW 342.43 Da. C-terminal tripeptide fragment (residues 11-13) of alpha-MSH. Retains anti-inflammatory properties without melanocortin receptor activation (no melanogenic/appetite effects). Not approved by any regulatory agency. No human clinical trials. Available grey-market.
Research suggests entry via PepT1 oligopeptide transporter, inhibiting NF-kappaB nuclear translocation (p65 subunit), reducing TNF-alpha, IL-1beta, IL-6, IL-8. Active in colonocytes, keratinocytes, macrophages. Mouse colitis: oral nanoparticle delivery reduced inflammation. Additional: MAPK/ERK inhibition, tight junction protein modulation.
No marketing authorization. No human trials. Dalmasso et al. (PLoS One 2008): KPV nanoparticles reduced DSS colitis in mice. Kannengiesser et al. (2008): murine colitis benefit. In vitro: reduces TNF-alpha, IL-1beta, IL-6 at 10-100 microM. No established human dosing.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 28 vendor listings
View pricing data across vendors and countries for KPV
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Bortezomib is marketed as Velcade (approved May 2003) for multiple myeloma and mantle cell lymphoma. Generic versions are available. Originally given intravenously, subcutaneous injection is now preferred as it causes significantly less nerve damage. The VISTA trial established bortezomib-based combination therapy as standard for newly diagnosed myeloma patients ineligible for transplant, with median time to disease progression of 24 months versus 16.6 months with older chemotherapy. Peripheral neuropathy (numbness and tingling in hands and feet) is the main dose-limiting side effect, affecting up to 30% of patients. Bortezomib transformed myeloma from a disease with a median survival of approximately 3 years to one where many patients live a decade or more with sequential treatments.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
